| Ranked All-Publication list | Historiographs | Glossary HistCite Guide About |
|
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James C, Ugo V, Le Couedic JP, Staerk J, et al. NATURE 434 (7037): 1144-1148, APR 28 2005 and the citing papers |
| Nodes: 181, Authors: 753, Journals: 66, Cited References: 5591, Words: 617
Yearly output | Document Type | Language | Institution | Institution with Subdivision | Country |
| View: Overview | Sorted by year, source, volume, issue, page. |
Page 2 of 2: [ 1 2 ]
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
|---|---|---|---|---|---|
| 101 | 1 | 6 | 101 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (3): 341-343 Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour | 0 | 0 |
| 102 | 38 | 212 | 102 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (4): 366-384 Khwaja A The role of Janus kinases in haemopoiesis and haematological malignancy | 0 | 0 |
| 103 | 4 | 147 | 103 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (5): 453-466 Deutsch VR; Tomer A Megakaryocyte development and platelet production | 0 | 0 |
| 104 | 3 | 21 | 104 2006 CANCER 106 (8): 1739-1743 Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; et al. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy | 0 | 0 |
| 105 | 6 | 66 | 105 2006 CANCER CELL 10 (1): 65-75 Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia | 0 | 0 |
| 106 | 1 | 54 | 106 2006 CANCER CELL 10 (1): 77-87 Kovacic B; Stoiber D; Moriggl R; Weisz E; Ott RG; et al. STAT1 acts as a tumor promoter for leukemia development | 0 | 0 |
| 107 | 2 | 107 | 107 2006 CELL DEATH AND DIFFERENTIATION 13 (5): 748-758 Braun T; Carvalho G; Fabre C; Grosjean J; Fenaux P; et al. Targeting NF-kappa B in hematologic malignancies | 0 | 1 |
| 108 | 1 | 103 | 108 2006 CLINICAL CANCER RESEARCH 12 (2): 332-339 Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW Erythropoietin biology in cancer | 0 | 1 |
| 109 | 2 | 200 | 109 2006 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 57 (2): 145-164 Walz C; Sattler M Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) | 0 | 1 |
| 110 | 1 | 148 | 110 2006 CURRENT CANCER DRUG TARGETS 6 (2): 107-121 Klampfer L Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 111 | 1 | 46 | 111 2006 CURRENT OPINION IN ONCOLOGY 18 (1): 62-68 Taki T; Taniwaki M Chromosomal translocations in cancer and their relevance for therapy | 0 | 0 |
| 112 | 1 | 67 | 112 2006 CURRENT OPINION IN ONCOLOGY 18 (2): 135-143 Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going | 0 | 1 |
| 113 | 1 | 56 | 113 2006 CURRENT OPINION IN PHARMACOLOGY 6 (2): 184-189 Sharples EJ; Thiemermann C; Yaqoob MM Novel applications of recombinant erythropoietin | 0 | 0 |
| 114 | 3 | 116 | 114 2006 DEVELOPMENT 133 (14): 2605-2616 Arbouzova NI; Zeidler MP JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions | 0 | 0 |
| 115 | 4 | 20 | 115 2006 EUROPEAN JOURNAL OF HAEMATOLOGY 77 (1): 57-60 Thurmes PJ; Steensma DP Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis | 0 | 0 |
| 116 | 8 | 23 | 116 2006 EUROPEAN JOURNAL OF HAEMATOLOGY 77 (3): 210-216 Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status | 0 | 0 |
| 117 | 2 | 125 | 117 2006 EXPERT OPINION ON BIOLOGICAL THERAPY 6 (3): 231-241 Leeman RJ; Lui VWY; Grandis JR STAT3 as a therapeutic target in head and neck cancer | 0 | 0 |
| 118 | 2 | 34 | 118 2006 GASTROENTEROLOGY 130 (7): 2031-2038 Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome | 0 | 0 |
| 119 | 1 | 86 | 119 2006 GENETICS 172 (3): 1683-1697 Mukherjee T; Schafer U; Zeidler MP Identification of Drosophila genes modulating janus kinase/signal transducer and activator of transcription signal transduction | 1 | 1 |
| 120 | 2 | 72 | 120 2006 GROWTH FACTORS 24 (1): 89-95 Ingley E; Klinken SP Cross-regulation of JAK and Src kinases | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 121 | 17 | 34 | 121 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 159-161 Cazzola M; Passamonti F Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders | 0 | 0 |
| 122 | 4 | 36 | 122 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 169-175 Arellano-Rodrigo E; Alvarez-Larran A; Reverter JC; Villamor N; Colomer D; et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status | 3 | 3 |
| 123 | 5 | 10 | 123 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (3): 411-412 Mnjoyan Z; Yoon D; Li J; Delhommeau F; Ashar-Kharghan V The effect of the JAK2 V617F mutation on PRV-1 expression | 0 | 0 |
| 124 | 1 | 9 | 124 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (3): 413-414 Percy MJ; Jones FGC; Creen AR; Reilly JT; McMullin MF The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis | 0 | 0 |
| 125 | 3 | 4 | 125 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (3): 415-416 Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; et al. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myelold metaplasia: analysis at two time points | 1 | 1 |
| 126 | 2 | 10 | 126 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (5): 719-720 Remacha AF; Nomdedeu JF; Puget G; Estivill C; Sarda MP; et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis | 0 | 0 |
| 127 | 1 | 22 | 127 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (8): 1100-1104 Vassiliou GS; Campbell PJ; Li J; Roberts I; Swanton S; et al. An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation | 0 | 0 |
| 128 | 2 | 115 | 128 2006 HEMATOLOGICAL ONCOLOGY 24 (2): 56-63 Reilly JT Idiopathic myelofibrosis: pathogenesis to treatment | 0 | 0 |
| 129 | 3 | 5 | 129 2006 HUMAN PATHOLOGY 37 (4): 500-500 Bousquet M; Brousset P Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation | 0 | 0 |
| 130 | 4 | 15 | 130 2006 HUMAN PATHOLOGY 37 (4): 500-502 Tzankov A; Heiss S Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) transtocation - reply | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 131 | 2 | 28 | 131 2006 INTERNATIONAL JOURNAL OF HEMATOLOGY 83 (5): 443-449 Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group | 0 | 0 |
| 132 | 3 | 42 | 132 2006 JOURNAL OF BIOLOGICAL CHEMISTRY 281 (26): 18177-18183 Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; et al. Activated Jak2 with the V617F point mutation promotes G(1)/S phase transition | 0 | 0 |
| 133 | 1 | 45 | 133 2006 JOURNAL OF IMMUNOLOGY 176 (11): 6425-6433 Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; et al. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin | 0 | 0 |
| 134 | 1 | 18 | 134 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (2): 170-177 Bock O; Busche G; Koop C; Schroter S; Buhr T; et al. Detection of the single hotspot mutation in the JH2 pseuclokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders | 2 | 2 |
| 135 | 8 | 18 | 135 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (3): 299-304 Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases | 0 | 0 |
| 136 | 7 | 10 | 136 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (3): 330-334 Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis | 0 | 0 |
| 137 | 1 | 6 | 137 2006 LANCET 367 (9511): 636-636 Butcher J; Summerskill W The research legacy of 2005 | 0 | 0 |
| 138 | 1 | 27 | 138 2006 LEUKEMIA 20 (1): 55-60 Cervantes F; Alvarez-Larran A; Arellano-Rodrigo E; Granell M; Domingo A; et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution | 0 | 0 |
| 139 | 1 | 10 | 139 2006 LEUKEMIA 20 (1): 157-158 Melzner I; Weniger MA; Menz CK; Moller P Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma | 0 | 0 |
| 140 | 7 | 69 | 140 2006 LEUKEMIA 20 (2): 200-205 De Keersmaecker K; Cools J Chronic myeloproliferative disorders: a tyrosine kinase tale | 2 | 4 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 141 | 2 | 8 | 141 2006 LEUKEMIA 20 (2): 350-353 James C; Delhommeau F; Marzac C; Teyssandier I; Le Couedic JP; et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis | 4 | 5 |
| 142 | 4 | 22 | 142 2006 LEUKEMIA 20 (3): 471-476 Quentmeier H; Macleod RAF; Zaborski M; Drexler HG JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders | 1 | 1 |
| 143 | 6 | 10 | 143 2006 LEUKEMIA 20 (3): 534-535 Vizmanos JL; Ormazabal C; Larrayoz MJ; Cross NCP; Calasanz MJ JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients | 1 | 1 |
| 144 | 5 | 9 | 144 2006 LEUKEMIA 20 (4): 736-737 Bellosillo B; Besses C; Florensa L; Sole F; Serrano S JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders | 2 | 2 |
| 145 | 9 | 63 | 145 2006 LEUKEMIA 20 (6): 971-978 Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained | 1 | 1 |
| 146 | 12 | 28 | 146 2006 LEUKEMIA 20 (6): 1055-1060 Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis | 1 | 1 |
| 147 | 2 | 7 | 147 2006 LEUKEMIA 20 (6): 1168-1169 Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation | 0 | 0 |
| 148 | 3 | 8 | 148 2006 LEUKEMIA 20 (7): 1319-1321 Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow | 0 | 0 |
| 149 | 3 | 8 | 149 2006 LEUKEMIA 20 (7): 1324-1326 Lea NC; Lim Z; Westwood NB; Arno MJ; Gaken J; et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia | 0 | 0 |
| 150 | 4 | 8 | 150 2006 LEUKEMIA 20 (8): 1453-1454 Park MJ; Shimada A; Asada H; Koike K; Tsuchida M; et al. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 151 | 5 | 143 | 151 2006 LEUKEMIA & LYMPHOMA 47 (2): 177-194 Nelson ME; Steensma DP JAK2 V617F in myeloid disorders: What do we know now, and where are we headed? | 3 | 5 |
| 152 | 1 | 7 | 152 2006 LEUKEMIA & LYMPHOMA 47 (2): 313-314 Lee JW; Soung YH; Kim SY; Nam SW; Park WS; et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas | 2 | 2 |
| 153 | 4 | 181 | 153 2006 LEUKEMIA & LYMPHOMA 47 (3): 381-396 Thiele J; Kvasnicka HM A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders | 2 | 4 |
| 154 | 17 | 34 | 154 2006 LEUKEMIA RESEARCH 30 (6): 739-744 Tefferi A; Pardanani A Mutation screening for JAK2(V617F): When to order the test and how to interpret the results | 2 | 2 |
| 155 | 5 | 173 | 155 2006 MAYO CLINIC PROCEEDINGS 81 (4): 553-563 Tefferi A; Elliot MA; Pardanani A Atypical myeloproliferative disorders: Diagnosis and management | 0 | 0 |
| 156 | 1 | 79 | 156 2006 MOLECULAR AND CELLULAR BIOLOGY 26 (11): 4052-4062 Mazurkiewicz-Munoz AM; Argetsinger LS; Kouadio JLK; Stensballe A; Jensen ON; et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor | 0 | 1 |
| 157 | 1 | 216 | 157 2006 MOLECULAR CELL 22 (6): 851-868 Liu BA; Jablonowski K; Raina M; Arce M; Pawson T; et al. The human and mouse complement of SH2 domain proteins - Establishing the boundaries of phosphotyrosine signaling | 0 | 0 |
| 158 | 2 | 21 | 158 2006 NEW ENGLAND JOURNAL OF MEDICINE 354 (20): 2166-2175 Yachimski PS; Chung RT; Sahani DV; Amrein PC; Misdraji J; et al. A 46-year-old woman with sudden onset of abdominal distention - Budd-Chiari syndrome, with centrilobular hepatocellular necrosis, sinusoidal dilatation, congestion, and red-cell extravasation consistent with the presence of venous outflow obstruction. Heterozygosity for factor V Leiden. V617F mutation in JAK2. | 0 | 1 |
| 159 | 1 | 15 | 159 2006 ONCOGENE 25 (9): 1434-1436 Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias | 4 | 4 |
| 160 | 1 | 25 | 160 2006 ONCOGENE 25 (18): 2679-2684 Weniger MA; Melzner I; Menz CK; Wegener S; Bucur AJ; et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation | 1 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 161 | 1 | 51 | 161 2006 ONCOGENE 25 (33): 4573-4584 Joliot V; Cormier F; Medyouf H; Alcalde H; Ghysdael J Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis | 0 | 0 |
| 162 | 1 | 19 | 162 2006 PATHOLOGIE BIOLOGIE 54 (4): 182-184 Berger R A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders | 0 | 0 |
| 163 | 1 | 98 | 163 2006 PHARMACOGENOMICS 7 (4): 597-612 Ma PC; Zhang XD; Wang ZHJ High-throughput mutational analysis of the human cancer genome | 0 | 0 |
| 164 | 8 | 36 | 164 2006 PLOS MEDICINE 3 (7): Art. No. E270 Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; et al. MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 165 | 1 | 39 | 165 2006 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 103 (16): 6224-6229 Jamieson CHM; Gotlib J; Durocher JA; Chao MP; Mariappan MR; et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation | 2 | 2 |
| 166 | 9 | 47 | 166 2006 REVUE DE MEDECINE INTERNE 27 (6): 473-477 Marie I; Herve F Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy | 0 | 0 |
| 167 | 23 | 185 | 167 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 174-207 Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: Therapeutic implications | 3 | 3 |
| 168 | 1 | 43 | 168 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 208-218 Briere JB Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management | 0 | 0 |
| 169 | 9 | 148 | 169 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 219-230 Thiele J; Kvasnicka HM Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders | 0 | 1 |
| 170 | 4 | 42 | 170 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 246-250 Mossuz P Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 171 | 4 | 74 | 171 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 251-259 Landolfi R; Di Gennaro L; Novarese L; Patrono C Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: Current insights and rationale for future studies | 0 | 0 |
| 172 | 2 | 31 | 172 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 260-266 Birgegard G Anagrelide treatment in myeloproliferative disorders | 0 | 0 |
| 173 | 2 | 51 | 173 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 267-275 Lengfelder E; Merx K; Hehlmann R Diagnosis and therapy of polycythemia vera | 0 | 0 |
| 174 | 2 | 35 | 174 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 283-288 Harrison CN Management of essential thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 trial | 1 | 1 |
| 175 | 2 | 35 | 175 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 295-304 Akkerman JWN Thrombopoietin and platelet function | 0 | 0 |
| 176 | 17 | 229 | 176 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 307-340 Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders | 0 | 0 |
| 177 | 27 | 69 | 177 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 341-351 Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients | 0 | 0 |
| 178 | 9 | 63 | 178 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 372-380 Griesshammer M Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia | 0 | 0 |
| 179 | 11 | 129 | 179 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 381-398 Bellucci S; Michiels JJ The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia | 0 | 0 |
| 180 | 3 | 41 | 180 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 417-421 Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; et al. Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 181 | 1 | 60 | 181 2006 TRANSFUSION MEDICINE AND HEMOTHERAPY 33 (3): 217-226 Gnatenko DV; Bahou WF Recent advances in platelet transcriptomics | 0 | 1 |
Page 2 of 2: [ 1 2 ]
Generated by HistCite 2006.08.14